The global vaccines market size was valued at USD 90 billion in 2025 and is projected to grow from USD 96.58 billion in 2026 to USD 169.91 billion by 2034 at a CAGR of 7.32% during the forecast period 2026-2034.
The global vaccines market is experiencing substantial growth, driven by increasing immunization programs, government support, and advancements in vaccine technology. The rise in demand for routine and specialized vaccines, including those for HPV, pneumococcal disease, and COVID-19, has propelled market expansion. Additionally, the emergence of next-generation platforms such as mRNA, recombinant protein subunits, and viral vector vaccines is reshaping the industry. Key players, including Pfizer, GSK, Sanofi, and emerging biotech firms, are investing heavily in R&D to develop innovative and personalized vaccines.
Further, the market is also characterized by strong international collaborations and strategic investments in vaccine production capabilities. Governments and organizations such as WHO, Gavi, and CEPI are funding large-scale immunization initiatives to improve global coverage, especially in low-income regions. The below graph depicts the distribution of annual vaccine doses across different procurement channels.
Source: United Nations Children's Fund (UNICEF), World Health Organization (WHO), and Straits Research
The global vaccine procurement landscape is diverse, with self-procuring middle-income countries (MICs) leading at 40% of annual doses, followed by self-procuring high-income countries (HICs) at 24%. UNICEF and PAHO play vital roles in supporting low- and middle-income countries, with Gavi-backed UNICEF procurement at 13% and PAHO’s Revolving Fund at 3%. While MICs are increasingly self-reliant, low-income countries (LICs) still depend on UNICEF (8%), highlighting the need for continued global funding and procurement support to ensure equitable vaccine access.
The success of mRNA-based COVID-19 vaccines has accelerated expansion beyond COVID-19, with candidates targeting flu, RSV, HIV, CMV and other emerging infectious. In addition, combination and endemic disease vaccines highlight the shift towards scalable, adaptable, and multi-target mRNA solutions.
Thus, the pipeline reflects the growing shift of vaccine developers towards mRNA technology for rapid, scalable, and adaptable vaccine development.
Moderna’s mRNA Vaccine Pipeline
Source: Company Vaccine Portfolio, Annual Report, ClinicalTrials.gov, and Straits Analysis
Governments across the world are adopting digital vaccine management apps to streamline immunization records, improve accessibility, and enhance public health initiatives.
Thus, this reflects growing reliance on technology to improve vaccine coverage, reduce administration burden, and facilitate real-time health monitoring.
Global Vaccine Management Apps and their Applications
Source: Health Authorities, and Straits Analysis
Download Free Sample Report to Get Detailed Insights.
Governments and global health organizations are expanding immunization programs to improve public health and prevent disease outbreaks. Countries have established national vaccination schedules and digital immunization tracking systems to ensure widespread coverage.
Thus, such initiatives, coupled with digital vaccine tracking and funding support, are driving vaccines market expansion.
Global Immunization Programs by Country
Source: Health Authorities, Immunization Programs, and Straits Analysis
Pharmaceutical companies and biotech firms are increasing R&D investments to develop next-generation vaccines, improve efficacy, and expand indications. Advancements in mRNA technology, personalized cancer vaccines, and universal flu vaccines demonstrate the industry's shift toward innovation.
Thus, higher R&D investment is driving vaccine innovation and market expansion.
Frequent vaccine stockouts owing to procurement delays, funding gaps, distribution issues, and inaccurate demand forecasting pose a major challenge to immunization programs, limiting the growth of market.
Rising awareness, aging populations, and government recommendations are driving demand for adult immunization and travel vaccines. Increased global mobility and emerging infectious diseases further support market expansion.
U.S. Vaccine Recommendation Chart
Source: Centers for Disease Control and Prevention (CDC), and Straits Analysis
The global market is bifurcated into monovalent vaccines and multivalent vaccines. Multivalent vaccines segment is expected to register the fastest CAGR owing to its ability to provide immunity against multiple pathogens in a single dose, reducing the number of injections required, improving patient compliance, and enhancing immunization coverage.
The global market is oral, parenteral, and nasal. Parenteral segment accounted for the largest share driven by the widespread use of injectable vaccines, higher efficacy, and well-established immunization programs.
The market is categorized into viral vaccines and bacterial vaccines. Viral vaccines dominate the market owing to their widespread use in immunization programs against prevalent infectious diseases such as influenza, COVID-19, hepatitis, MMR, and HPV. The high burden of viral infections, continuous advancements in vaccine technology, and strong government support for large-scale immunization campaigns further drives their market dominance.
The market is categorized into adult and pediatric. Adult segment is expected to register the fastest CAGR owing to the rising awareness of adult immunization, increasing prevalence of infectious diseases among adults, and growing government recommendations for booster doses and travel vaccines.
Download Free Sample Reportto Get Detailed Insights.
North America holds a leading position in the vaccines market owing to the presence of major players such as Pfizer, Inc., Moderna, Merck & Co., Inc., and Johnson & Johnson, which drive innovation and production. Strong government immunization programs, high healthcare expenditure, and rapid regulatory approvals further support market growth. Additionally, widespread public awareness campaigns and increasing adoption of novel vaccines contribute to the region’s dominance.
The Asia-Pacific region is expected to register the fastest CAGR during the forecast period owing to rising government initiatives for immunization, increasing healthcare investments, and growing awareness of vaccine-preventable diseases. Expanding biotechnology and pharmaceutical industries, particularly in China and India, further support market growth.
Source: Clinton Health Access Initiative (CHAI) – China and Straits Research
Source: World Integrated Trade Solution (WITS), and Straits Research
Source: GAVI-UK, and Straits Research
Key players in the industry are focus on adopting key business strategies, such as strategic collaborations, product approvals, acquisitions, and product launches, to gain a strong foothold in the market.
Bavarian Nordic Inc. is an emerging player in the vaccine market, specializing in viral vector-based vaccines for infectious diseases such as smallpox, monkeypox, and rabies.
Recent developments by Bavarian Nordic Inc.:
Customize This Report to Match Your Strategic Objectives
Author's Details
Research Associate
Mitiksha Koul is a Research Associate with 2 years of experience in market research. She focuses on analyzing industry trends, competitive landscapes, and growth opportunities to support strategic decision-making. Mitiksha’s strong analytical skills and research expertise enable her to deliver actionable insights that help businesses adapt to evolving market dynamics and achieve sustainable growth.
We are featured on:
sales@straitsresearch.com